Sonoma Pharmaceuticals (SNOA) Cost of Revenue (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Cost of Revenue of $3.4 million for Q1 2026, up 51.84% year-over-year from $2.2 million in Q1 2025, and up 25.23% quarter-over-quarter from $2.7 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Cost of Revenue (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Cost of Revenue history runs 17 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 51.84% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $12.1 million (up 37.3% YoY), while the FY2026 annual figure was $12.1 million, up 37.3% from the prior year.
- Cost of Revenue for Q1 2026 stood at $3.4 million, up from $2.7 million in the prior quarter.
- The five-year high for Cost of Revenue was $3.5 million in Q3 2025, with the low at $1.7 million in Q4 2023.
- The 5-year median for Cost of Revenue is $2.2 million (2023), against an average of $2.3 million.
- The sharpest annual moves came in 2022 and 2025: Cost of Revenue fell 28.29% in 2022, then surged 57.08% in 2025.
- Sonoma Pharmaceuticals' Cost of Revenue stood at $2.1 million in 2022, then fell by 20.59% to $1.7 million in 2023, then surged by 36.71% to $2.3 million in 2024, then advanced by 17.65% to $2.7 million in 2025, then increased by 25.23% to $3.4 million in 2026.
- Business Quant data shows SNOA's Cost of Revenue at $3.4 million in Q1 2026, $2.7 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.19 Mn | -145,899.91 | 2.58 Mn | 3.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.83 Mn |
| Jun 30, 2026 | 3.83 Mn |
| Mar 31, 2026 | 3.38 Mn |
| Mar 31, 2026 | 3.38 Mn |
| Dec 31, 2025 | 2.70 Mn |
| Dec 31, 2025 | 2.70 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Mar 31, 2025 | 2.23 Mn |
| Mar 31, 2025 | 2.23 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 2.22 Mn |
| Sep 30, 2024 | 2.22 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Mar 31, 2024 | 2.35 Mn |